Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Oct 29, 2026
Reporting period
Not applicable
Filed with the SEC
Nov 2, 2026
DirectorGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0002160743-26-000012
Filed / recorded
Nov 2, 2026, 9:01 PM UTC
Added to OQRO
Nov 3, 2026, 7:43 AM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
Bambusa Therapeutics, Inc.
Issuer CIK
2044950
Ticker
BBTX
Reporting person
Shanshan Xu
Relationship
Director, Officer, 10% owner
Officer title
See remarks
Security
Restricted Stock Units
Table
Derivative (Table II)
Transaction date
Oct 29, 2026
Transaction code
A
Shares / units
758,204
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
758,204
Ownership form
Direct
Amendment
No
Footnotes from the filing
Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the RSUs subject to the award shall vest upon the Administrator (as defined in the Issuer's 2026 Equity Incentive Plan) determining and certifying the achievement of the weighted average price of a share of the Issuer's common stock equals or exceeds $32 for any period of 30 consecutive trading days following April 1, 2027 and prior to April 1, 2030.
A Schedule 13D means the holder owns more than 5% and keeps the option to push for changes: board seats, a sale, buybacks. It must be filed within 5 business days.
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
A Bambusa Therapeutics director paid $2.7M out of pocket for Bambusa Therapeutics shares. 2 other people at Bambusa Therapeutics bought some too, in the same month.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.